sidebar
sidebar
A Sea Change in MS Treatment — The Potential of Small Molecules

PLEASE NOTE:
As required by the ACCME, all participants must read the information below before proceeding to this activity.
After doing so, please click the Launch Activity button at the bottom of this page.
 



CHAIR
Bruce A. Cohen, MD Bruce A. Cohen, MD
Professor
Davee Department of Neurology
Feinberg School of Medicine
Northwestern University
Chicago, Illinois
FACULTY

Bruce A. C. Cree, MD, PhD, MCR Bruce A. C. Cree, MD, PhD, MCR
Assistant Professor of Neurology
Multiple Sclerosis Center
University of California,
  San Francisco
San Francisco, California

Mark S. Freedman, HBSc, MSc, MD Mark S. Freedman, HBSc, MSc, MD
Professor of Neurology
Department of Medicine
University of Ottawa
Ottawa, Ontario, Canada
Douglas S. Goodin, MD Douglas S. Goodin, MD
Professor of Neurology
Medical Director
Multiple Sclerosis Center
University of California, San Francisco
San Francisco, California


This CME activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME/CE activities may not contain the most up-to-date information available.

Click here to view our current activities in Neurology.

PROGRAM OVERVIEW

Recent advances in understanding the pathogenesis of multiple sclerosis and its relation to treatment, the importance of early intervention, and the use of novel small-molecule therapies are resulting in expanded treatment options and new hope for patients with this debilitating disease. Please join a panel of neurology experts at A Sea Change in MS Treatment—The Potential of Small Molecules to discuss these exciting new developments and the evolving strategies and controversies in optimizing outcomes for patients with multiple sclerosis. 


ACTIVITY AGENDA
  • New Perspectives on the Pathogenesis of MS
    Douglas S. Goodin, MD

  • Goals of Optimal Therapy
    Bruce A. Cohen, MD

  • Current Therapies and Role of Emerging Small-Molecule Therapies in MS – Evolving Strategies
    Bruce A.C. Cree, MD, PhD, MCR

  • Controversies in MS
    Mark S. Freedman, HBSc, MSc, MD

  • Panel Discussion
    Faculty

top


TARGET AUDIENCE

This CME/CE activity is designed for neurologists and other clinicians who are involved in the treatment of patients with multiple sclerosis.

ACTIVITY GOAL

The goal of this program is to provide clinicians with state-of-the-science, clinically relevant information concerning the pathophysiology of MS, novel treatments in development, and new strategic approaches that will enable them to optimize therapy for their patients with multiple sclerosis.

top

LEARNING OBJECTIVES

  • Assess the etiology, pathophysiology, and course of MS in order to determine appropriate treatment approaches that improve patient outcomes.
  • Understand the inflammatory and neurodegenerative response in MS and potential targets for intervention to select optimal strategies for the care of MS patients.
  • Understand the MOA, efficacy, and safety of current and emerging agents used in the treatment of patients with MS.

top


CME Information: Physicians

Statement of Accreditation
Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Projects In Knowledge designates this educational activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CE Accreditation: Nurses

This continuing nursing education activity was approved by the Delaware Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

This program is approved for 1.5 contact hours.
DNA # is 08-05-03.

CE Information: Pharmacists

Projects In Knowledge is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This activity has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. The ACPE Universal Program Number assigned to the program, for 1 contact hour (0.1 CEU) is 052-000-08-045-H01-P.

Contract for Mutual Responsibility in CME/CE
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience. For more information on the contract, click here.

top


DISCLOSURE INFORMATION
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards of Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

For complete prescribing information on the products discussed during this CME activity, please see your current Physicians' Desk Reference (PDR).

Bruce A. Cohen, MD, has served as a consultant for and participated in the speakers bureaus of Bayer Pharmaceuticals, Biogen-Idec, EMD-Serono, Pfizer Inc, and Teva Neuroscience; has received consulting fees from Bayer Pharmaceuticals, EMD-Serono, Genentech, Inc, and Teva Neuroscience; has received honoraria directly from Bayer Pharmaceuticals, Biogen-Idec, EMD-Serono, and Teva Neuroscience; and has ownership interest in Abbott Laboratories and CVS-Caremark.

Bruce A.C. Cree, MD, PhD, MCR, has received grant/research support from BioMS Medical, EMD-Serono, and Genentech, Inc; and has participated in the speakers bureaus of Biogen-Idec and Teva Neuroscience.

Mark S. Freedman, HBSc, MSc, MD, has no potential conflicts of interest to disclose.

Douglas S. Goodin, MD, has received grant/research support from Bayer Pharmaceuticals, Biogen-Idec, Novartis Pharmaceuticals Corporation, and Schering-Plough Corporation; has served as a consultant for Bayer Pharmaceuticals, EMD-Serono, and Schering-Plough Corporation; has participated in the speakers bureaus of Bayer Pharmaceuticals, EMD-Serono, Schering-Plough Corporation, and Teva Neuroscience; has received consulting fees from Bayer Pharmaceuticals, EMD-Serono, and Schering-Plough Corporation; and has received honoraria directly from Bayer Pharmaceuticals, EMD-Serono, Schering-Plough Corporation, and Teva Neuroscience.

Peer Reviewer has no significant relationships to disclose.

Projects In Knowledge’s staff members have no significant relationships to disclose.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the physician caring for the patient.

This independent CME/CE activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

top

 


Requires Flash 8 or higher
and high-speed internet 

 
 
 
 


Copyright © 1997-2017, Projects In Knowledge, Inc. All rights reserved.
PROJECTS IN KNOWLEDGE • Overlook at Great Notch • 150 Clove Road, 10th Floor • Little Falls, New Jersey 07424 (973) 890-8988

For questions or comments regarding this web site please contact: Webmaster
Privacy Policy

 

Release Date:
   June 30, 2008.

Termination Date:
   June 30, 2009.

Release Date for Nurses:
   June 30, 2008.

Termination Date for Nurses:
   June 30, 2010.

Estimated time for completion of this activity: 1.5 hours

This independent CME/CE activity is supported by educational grants from Novartis Pharmaceuticals Corporation



1842